MetaCap

Immutep (IMMP) vs SCYNEXIS (SCYX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Immutep (IMMP) has outperformed SCYNEXIS (SCYX) over the past year, gaining 80.8% versus a loss of 56.3%. Over five years, IMMP leads with a -8.5% price change compared with -96.0% for SCYX. SCYNEXIS is the larger company by market cap ($23.7 million vs $22.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMMP+80.81%SCYX-56.25%
+375%+134%-107%
Nov 21, 20251 yearNov 20, 2026
IMMP-18.37%SCYX-95.83%
+115%+4%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMMP versus SCYX key metrics
MetricIMMPSCYX
Share price$3.11$2.38
Market cap$22.92M$23.69M
1-day change-9.06%-8.64%
YTD return+8.74%-52.93%
1-year return+80.81%-56.25%
5-year return-8.53%-96.00%
EPS (TTM)$-7.30$-0.23
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$20.60M
Revenue growth (YoY)—+449.95%
Net income (latest FY)—$-8.61M
Operating margin—-78.03%
Net margin—-41.79%
52-week high$70.60$9.12
52-week low$2.66$2.30
Distance from 52-week high-95.59%-73.90%
Analyst consensusnonestrong_buy
Avg. price target upside+864.63%+1426.47%
Average volume26.07K225.27K
Shares outstanding7.37M9.95M
Employees—18
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IMMP has outperformed SCYX by 137.1 percentage points over the past year.

About Immutep

IMMP stock →

Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer.

Health Care · Biotechnology: Pharmaceutical Preparations

About SCYNEXIS

SCYX stock →

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence.

Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees

IMMP vs SCYX FAQ

Which is bigger, Immutep or SCYNEXIS?

SCYNEXIS (SCYX) is larger, with a market capitalization of $23.69M compared with $22.92M for Immutep (IMMP).

Which stock has performed better over the past year, IMMP or SCYX?

IMMP returned +80.81% over the past 12 months, compared with -56.25% for SCYX (price return, excluding dividends). Past performance does not predict future results.

Are Immutep and SCYNEXIS in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons